ARIX BIOSCIENCE PLC — Board/Management Information 2017

Jul 10, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4837K

Arix Bioscience Plc

10 July 2017

Arix Bioscience plc appoints Robert Lyne as General Counsel

LONDON, 10 July, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global healthcare and life science company supporting medical innovation, today announced that it has appointed Robert Lyne as its General Counsel. 

In his role as General Counsel Mr Lyne will support the strategic and operational direction of the Company. He brings extensive relevant legal experience from both a corporate and private practice background. Most recently, Mr Lyne was a member of the legal team at Touchstone Innovations, and prior to that he worked at international law firm Bird & Bird LLP.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "We are delighted to welcome Robert to the team. This is a key appointment as we continue to grow, invest in and support medical innovation."

Robert Lyne commented: "I am very pleased to join Arix Bioscience, working alongside some of the most respected business builders in the life science industry. I am excited by Arix's potential, and am looking forward to playing a role in supporting its further development."

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

+44 (0) 20 7290 1052

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASSFFDWFWSEEW